🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

RecruitingNAAges 18 Years - anyAllPeking Union Medical College Hospital
NCT06168032 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients who agree to participate in the trial and sign the informed consents. 2. Male or female, ≥18 years old. 3. Diagnosed of lung carcinoma by histological and cytological examinations. 4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy. 5. Recorded history of COVID19 infection. 6. Sufficiently functional organs. 7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2. Exclusion Criteria: 1. Life expectance less than 3 months. 2. Less than 3 months since last confirmed COVID-19 infection. 3. Patients unable to return the hospital for follow-up. 4. Patients allergic to COVID-19 vaccine. 5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.
💊

What it tests

  • Any Chinese government-recommended COVID-19 booster vaccine
📍

Where

1 site
Peking Union Medical College Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy